ContraFect

ContraFect Corporation is a biotechnology company focused on developing innovative biologic therapies to combat life-threatening, drug-resistant infections. Operating in the healthcare and pharmaceutical market, ContraFect primarily serves hospitals, healthcare providers, and patients suffering from severe bacterial infections. The company's core products include lysins and direct lytic agents, which are designed to target and destroy antibiotic-resistant bacteria. ContraFect's business model revolves around research and development, clinical trials, and eventual commercialization of its therapies. Revenue is generated through product sales, partnerships, and licensing agreements. The company aims to address the growing global health crisis of antibiotic resistance by providing effective and novel treatment options. Keywords: biotechnology, drug-resistant, infections, lysins, lytic agents, healthcare, pharmaceutical, antibiotic resistance, biologic therapies, clinical trials.